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Vaccination is one of the public health measures that have the greatest impact on the reduction of the burden from infectious diseases and associated mortality, 
especially in children. It is estimated that, each year worldwide, 
vaccines prevent up to 3 million deaths [1,2]. Immunization is 
one of the most cost-effective interventions to save and prolong 
life [3]. Expanded Programme on Immunization (EPI), which 
was launched by the World Health Organization in the year 1974, 
aimed to protect all the children of the world from six vaccine-
preventable diseases – Bacille Calmette–Guérin vaccine for 
tuberculosis, diphtheria-pertussis-tetanus vaccine, and oral polio 
and measles vaccine. Hepatitis B vaccine was introduced later in 
the 1980s [4].
In India, EPI was flagged off in 1978, mainly in the urban 
areas, for immunizing children <1 year of age group. Through 
the subsequent years, more vaccines were included in the EPI 
program, for example, oral polio vaccine in 1979 and the vaccine 
to immunize pregnant mothers with tetanus toxoid vaccine 
in 1983. In 1985, the program was renamed as the Universal 
Immunization Program (UIP) focusing mainly on infants and 
pregnant mothers. Measles vaccine was included in the program 
in 1990 and the program was expanded to spread across the 
country [5]. India included the 2nd dose of measles vaccine in the 
National Immunization Program in 2010. Hepatitis B vaccination 
was included in UIP in 2002–2003, and in 2011, it covered whole 
of India.
With the financial support from global alliance for vaccine 
and immunization, Indian government included Pentavac vaccine 
as a pilot project in few selected states in 2011, which was later 
scaled up in all states under the UIP by 2015 [6]. According to 
the recommendation of National Technical Advisory Group 
of India, Government of India included four new vaccines for 
polio (injectable), Rotavirus, rubella, and Japanese encephalitis 
(179 districts) in the UIP for whole India [7]. The UIP aims to 
vaccinate 26 million newborns and 30 million pregnant mothers 
annually for vaccines covered under the program [8]. More than 9 
million immunization sessions are conducted annually with nearly 
27,000 cold chain points across the country [8]. Disease burden, 
safety, efficacy, cost-effectiveness, and operational requirements 
of the vaccination program are some of the important factors 
considered before including a vaccine in the national UIP [6].
The Government of India has recently decided to include 
pneumococcal conjugate vaccine (PCV) in UIP. For the 1st time, 
millions of children in India would be receiving protection for free 
against the leading cause of pneumonia, which kills more under-
five children than any other infectious disease [9] Until now, PCV 
was only available in the private sector in India, putting it beyond 
the reach of most of the population. By making it available under 
the UIP, the Government of India has ensured equitable access to 
the underprivileged and underserved.
PCV was launched by the Union Health Minister, Shri JP 
Nadda on May 13, 2017, at Mandi, Himachal Pradesh [9]. With 
its phased introduction, nearly 2.1 million children in Himachal 
Pradesh (all 12 districts), parts of Bihar (17 of 38 districts), and 
Uttar Pradesh (6 of 75 districts) have been vaccinated with PCV in 
the 1st year. This was followed by introduction in Madhya Pradesh 
and Rajasthan next year, and eventually, coverage will be expanded 
across the entire country in a phased manner, in the coming years. 
With the introduction of PCV in UIP, protection will be offered 
to the children from 12 diseases (tuberculosis, polio, diphtheria, 
pertussis, tetanus, hepatitis B, measles, Haemophilus influenzae 
b, Rotavirus diarrhea, Japanese encephalitis (in endemic states), 
rubella, and pneumococcal disease) [10].
Introduction of PCV in the UIP will reduce child deaths 
from pneumococcal pneumonia. Further, it would also reduce 
the number of children being hospitalized for pneumonia and, 
therefore, reduce the economic burden on families and the health 
cost burden on the country. As the schedule of pentavalent and 
pneumococcal vaccines is same (6, 10, and 14 weeks) in the 
present vaccination schedule under UIP, the introduction of 
this new vaccine will not affect the frequency of visit to health 
facility, which, in turn, will not affect the cost and coverage of 
the program.
Pneumonia is the single largest infectious cause of death 
among under-five children worldwide, accounting for about 
0.92 million deaths every year. It is estimated that 1 in 6 deaths 
in under-five children was due to pneumonia in 2015 [11]. More 
than 80% of deaths associated with pneumonia occur in children 
during the first 2 years of life [12]. Pneumococcal disease is also 
the number one vaccine-preventable cause of death in children 
under five, globally and in India [9]. Pneumococcal pneumonia, in 
particular, is a major public health concern for children globally. 
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This infection accounts for 18% of all severe pneumonia cases 
and 33% of all pneumonia deaths worldwide [12,13].
India has a pneumonia mortality rate of 7/1000 live births [14]. 
Similar to the global scenario, pneumonia due to Streptococcus 
pneumoniae (pneumococcal pneumonia) is responsible for a 
large portion of pneumonia episodes and deaths in India. In 2010, 
3.6 million episodes of severe pneumonia and 0.35 million all-
cause pneumonia deaths occurred in children under the age of 
5 years in India. Among those, 0.56 million episodes (16%) of 
severe pneumonia and 0.10 million deaths (30%), respectively, 
were caused by pneumococcal pneumonia [12].
Introduction of PCV in UIP in India is a right step toward 
achieving one of the important targets of the sustainable 
development goals, i.e., by 2030, to end the preventable deaths of 
newborns and children under 5 years of age and to reduce under-
five mortality to as low as 25/1000 live births [15].
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